- Home
- CHI vs VALN Comparison
CHI vs VALN Comparison
Compare CHI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | VALN |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 875.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHI | VALN |
|---|---|---|
| Price | $11.47 | $11.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 191.6K | 17.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.62 |
| Revenue Next Year | N/A | $5.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.41 | $5.43 |
| 52 Week High | $11.75 | $12.25 |
Technical Indicators
Market Signals| Indicator | CHI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 59.78 |
| Support Level | $10.93 | $8.29 |
| Resistance Level | $11.50 | $12.24 |
| Average True Range (ATR) | 0.18 | 0.40 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 43.13 | 61.13 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.